Xencor, Inc.

DB:XE9 Stock Report

Market Cap: €1.6b

Xencor Valuation

Is XE9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XE9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XE9 (€22.6) is trading above our estimate of fair value (€17.44)

Significantly Below Fair Value: XE9 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XE9?

Key metric: As XE9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XE9. This is calculated by dividing XE9's market cap by their current revenue.
What is XE9's PS Ratio?
PS Ratio19.8x
SalesUS$85.16m
Market CapUS$1.69b

Price to Sales Ratio vs Peers

How does XE9's PS Ratio compare to its peers?

The above table shows the PS ratio for XE9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.7x
BIO3 Biotest
1.4x3.6%€1.3b
FYB Formycon
14.9x32.0%€905.8m
HPHA Heidelberg Pharma
12.5x16.6%€105.8m
MDG1 Medigene
2x13.3%€15.2m
XE9 Xencor
19.8x28.4%€1.7b

Price-To-Sales vs Peers: XE9 is expensive based on its Price-To-Sales Ratio (19.8x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does XE9's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.4x3.6%US$1.39b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
XE9 19.8xIndustry Avg. 8.2xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XE9 is expensive based on its Price-To-Sales Ratio (19.8x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is XE9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XE9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio19.8x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: XE9 is expensive based on its Price-To-Sales Ratio (19.8x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XE9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€22.60
€31.44
+39.1%
15.5%€38.22€21.02n/a11
Dec ’25€23.80
€30.25
+27.1%
20.2%€38.41€19.21n/a10
Nov ’25€19.00
€30.26
+59.3%
24.5%€45.73€18.29n/a11
Oct ’25€17.60
€29.36
+66.8%
24.2%€44.74€17.89n/a11
Sep ’25€15.30
€29.26
+91.3%
23.9%€44.83€18.83n/a11
Aug ’25€18.60
€31.01
+66.7%
22.6%€46.18€19.39n/a12
Jul ’25€17.70
€31.50
+78.0%
21.9%€46.55€19.55n/a12
Jun ’25€21.60
€33.07
+53.1%
26.5%€53.40€20.26n/a12
May ’25€19.30
€33.72
+74.7%
26.5%€54.58€20.70n/a12
Apr ’25€20.60
€34.45
+67.2%
29.5%€53.52€20.30n/a12
Mar ’25€21.00
€34.45
+64.1%
29.5%€53.52€20.30n/a12
Feb ’25€17.00
€34.25
+101.5%
23.3%€51.59€20.27n/a11
Jan ’25€19.00
€34.78
+83.1%
26.4%€53.75€20.04n/a11
Dec ’24€16.40
€37.17
+126.6%
26.5%€55.22€20.59€23.8014
Nov ’24€16.40
€41.21
+151.3%
20.5%€55.81€25.54€19.0014
Oct ’24€19.00
€41.21
+116.9%
20.5%€55.81€25.54€17.6014
Sep ’24€20.00
€40.42
+102.1%
19.8%€54.03€24.72€15.3014
Aug ’24€21.60
€39.36
+82.2%
20.2%€53.04€24.27€18.6014
Jul ’24€22.80
€41.26
+80.9%
19.4%€55.05€25.19€17.7014
Jun ’24€25.20
€41.26
+63.7%
19.4%€55.05€25.19€21.6014
May ’24€24.00
€41.03
+71.0%
18.5%€53.54€24.50€19.3014
Apr ’24€24.80
€43.41
+75.1%
18.3%€55.93€25.59€20.6015
Mar ’24€30.00
€43.41
+44.7%
18.3%€55.93€25.59€21.0015
Feb ’24€29.80
€41.98
+40.9%
19.8%€54.39€24.89€17.0015
Jan ’24€23.80
€43.79
+84.0%
19.3%€55.57€28.25€19.0014
Dec ’23€28.40
€46.37
+63.3%
19.2%€58.57€29.78€16.4014

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xencor, Inc. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research